TSXV: RKV
Redefining Cancer Care
Rakovina Therapeutics Inc. (TSX-V: RKV) is leveraging cutting-edge AI platforms to compress drug discovery timelines from years to just months.
Download Investor Kit — It’s free
Learn More About Our Research
TOP UNDERVALUED BIOTECH STOCK
PROJECTED $18B ANNUAL MARKET
$5 MILLION RAISED IN 2024
PRE-CLINICAL DRUG DISCOVERY
IN PARTNERSHIP WITH UBC
HEADQUARTERS IN CANADA
WHAT WE DO
Rakovina (TSX-V: RKV) screens billions of compounds at 100x speed, facilitating accelerated progression to clinical development.
Our Vision
Our mission is to deliver hope to patients and families by creating therapies that extend lives, improve outcomes, and redefine possibilities in cancer treatment.
Unique Investment Opportunity
Recent preclinical deals, such as the $1.5B Artios - Novartis and the $1.2B Remix - Sanofi deals, highlight the immense value Rakovina could unlock.
Advanced Technology: Rakovina (TSX-V: RKV) combines AI-driven innovation with a proven track record of success
World-Class Expertise: Advisory board member Dr. Artem Cherkasov, PhD — UBC professor and pioneer of the Deep Docking platform—has driven multiple successful drug licensing deals with major pharmaceutical companies
Download Investor Kit — It’s free
AI-Driven Drug Discovery
Deep Docking and Variational AI Enki are distinct computational modeling techniques to rapidly evaluate billions of compounds to identify novel therapeutic drug candidates.
Deep Docking delivers a 6,000x enrichment in drug candidate identification, cutting discovery timelines by up to 100x
Variational AI Enki creates entirely new chemical structures optimized for biological targets, accelerating drug development
Building on the foundation of the first-generation Deep Docking system, which identified a compound licensed to Roche in a $142M deal — the largest in University of British Columbia's (UBC) history
The second-generation system now powers Rakovina’s accelerated discovery process
Screened COVID-19 compounds in just
Rapid Progression to Preclinical and Clinical Development
Rakovina's pipeline includes three series targeting DNA-Damage Response (DDR) mechanisms.
The kt-3000 series features a preclinical candidate advancing through development to address hard-to-treat cancers such as breast, ovarian, and prostate
The kt-2000 & kt-5000 series are in discovery stages, with compounds being optimized to identify lead candidates
Access to UBC’s state-of-the-art wet-lab facilities accelerating the validation of AI-identified compounds
Experienced management and advisory teams with a proven track record of advancing innovative cancer therapies from discovery to commercialization.
Artem Cherkasov, PhD, the creator of Deep Docking with 200+ papers and 8 licensed drugs expertise
Petra Hamerlik, PhD, a former AstraZeneca DDR program director, bringing world-class DDR expertise
Download Investor Kit — It’s free
Unique Investment Opportunity
Deep Docking revolutionizes drug discovery by evaluating billions of compounds to identify the most promising candidates.
Benefits
High-Yield Discovery: Rapidly screens extensive chemical libraries to pinpoint top candidates
Accelerated Timelines: Reduces the discovery phase from years to months, significantly lowering costs
Maximized Success Rates: Predicts safety and efficacy with exceptional precision
enrichment in drug candidates identification
speed of drug candidates discovery
By combining Deep Docking with Variational AI’s generative capabilities, we expand our pipeline faster and more effectively than ever before.
Innovative Molecule Optimization
Screen Billions of Compounds in Record Time
Recent
Milestones
Successfully raised $5 million in 2024 to advance preclinical developments.
Partnerships with UBC, Dr. Artem Cherkasov, and Variational AI accelerate discovery efforts.
Named among the Top Undervalued Biotech Stocks on the TSX Venture Exchange.
Meet Our Leadership
At Rakovina Therapeutics, innovation is driven by a team of experts in oncology, biotechnology, and drug discovery.
Jeffrey Bacha, BSc, MBA
Executive Chairman
Over 25 years of leadership in biotech innovation
Mads Daugaard, PhD
President & CSO
Renowned expert in DNA-damage response mechanisms
John Langlands, PhD
COO
A proven track record in advancing therapeutic pipelines
Scientific Advisory Board
Artem Cherkasov, PhD
AI & Medicinal Chemistry Advisor
Creator of the Deep Docking™ AI Platform
Petra Hamerlik, PhD
DDR Program Advisor
Former head of DDR programs at AstraZeneca
Download Investor Kit — It’s free
Legal Disclaimer
1. General Information and Liability
This landing page is provided and maintained by Fairfax Partners Inc. ("Fairfax") exclusively for informational purposes related to Rakovina Therapeutics Inc. ("Rakovina"). Fairfax assumes no responsibility for the accuracy, completeness, or timeliness of any information provided on this page. The content herein is composed of public, non-material information obtained from sources deemed reliable but is not guaranteed by Fairfax as to its accuracy or completeness.
2. No Endorsement or Financial Advice
Fairfax does not own shares or any other financial interests in Rakovina Therapeutics Inc. Fairfax's role is strictly limited to the creation, maintenance, and promotion of this landing page as part of a sponsored campaign. Fairfax does not provide, endorse, or imply any form of financial, legal, or investment advice, nor does it recommend or endorse the purchase or sale of any securities or financial instruments related to Rakovina Therapeutics Inc. or any other entity. Fairfax was compensated CA$120,000 by Rakovina Therapeutics Inc. for its services in managing and promoting this campaign across digital platforms, including Facebook, YouTube, TikTok, and Instagram.
3. Risk Disclaimer
Investing in securities, including those of Rakovina Therapeutics Inc., inherently involves risks, including the potential loss of principal. Neither Fairfax nor Rakovina Therapeutics Inc. assumes responsibility for any direct, indirect, consequential, or incidental damages or losses incurred by any party arising from the use or reliance on the information presented on this page.
4. Forward-Looking Statements
This landing page and associated promotional materials may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. These statements reflect Rakovina Therapeutics Inc.’s current expectations and views about future events. Forward-looking statements are not historical facts; they often include terms like "expects," "anticipates," "plans," "believes," and similar phrases that indicate expectations of future outcomes.
These statements involve risks, assumptions, and uncertainties that could cause actual results to differ significantly from those expressed or implied. No assurance can be given that these expectations will prove accurate. Rakovina Therapeutics Inc.’s forward-looking statements are based on assumptions regarding its business activities and strategies. Such statements are subject to risks beyond Rakovina Therapeutics Inc.’s control, including changes in market conditions, regulatory environments, and other uncertainties.
Rakovina Therapeutics Inc. does not undertake any obligation to update forward-looking statements, except as required by law. Additional details can be found in the "Forward-Looking Statements" and "Risk Factors" sections of Rakovina Therapeutics Inc.’s public filings, available at www.sedar.com.
5. Due Diligence and Professional Advice
All visitors to this landing page are strongly encouraged to perform their own comprehensive due diligence before making any investment decisions. This includes, but is not limited to, reviewing publicly available financial statements, reports, and other relevant documents related to Rakovina Therapeutics Inc., or consulting with independent, qualified financial advisors or legal professionals who can provide tailored advice based on individual circumstances.
6. No Offer or Solicitation
Nothing on this page constitutes an offer to sell or a solicitation to buy any securities or financial instruments. Any investment decision made by a visitor is solely the responsibility of the individual and should be based on their own analysis and judgment. The information on this page should not be considered a substitute for professional investment advice.
7. Limitation of Fairfax’s Role and Responsibilities
Fairfax’s involvement with this landing page and associated promotional materials is limited to providing a platform for information dissemination as directed by Rakovina Therapeutics Inc. Fairfax has no control over, and assumes no responsibility for, the content provided by Rakovina Therapeutics Inc. or any actions taken by visitors based on such content. Fairfax is not liable for any errors, omissions, or inaccuracies in the content provided, nor for any actions taken based on the information on this page.
8. Acknowledgment and Agreement
By accessing or using this landing page, you acknowledge that you have read, understood, and agreed to be bound by this legal disclaimer. You also acknowledge and accept that any reliance on the information contained on this page is at your own risk.